Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

is and a growing percentage throughout the course of the

disease.

-- American Society of Hematology (ASH) Meeting -- Numerous VELCADE

abstracts are expected to be featured at the ASH meeting in December

2007. These abstracts may include data from two large, randomized

Phase III trials in patients with newly diagnosed MM. Data may also be

presented on additional VELCADE based combinations in front-line MM and

Non-Hodgkin's Lymphoma (NHL).

Clinical Pipeline Highlights

In addition to VELCADE, the Company continues to advance ten novel molecules in the areas of cancer and inflammatory diseases. Recent progress included the following:

-- MLN0002 - The Company completed enrollment in the bridging trials

designed to evaluate the safety, tolerability, pharmacokinetics and

pharmacodynamics of this novel antibody to the target alpha 4 beta 7,

derived from a new commercially scalable cell line. The Company is

tracking toward pivotal trials with MLN0002 in ulcerative colitis and

Crohn's disease.

-- MLN3897 - The Company is on track to announce top-line results for this

novel CCR1 inhibitor by year end from a 191-patient Phase II proof-of-

concept trial in rheumatoid arthritis.

-- MLN4924 - In October 2007, the Company presented data on this

Millennium-discovered molecule and target at the European Organization

for Research and Treatment of Cancer (EORTC) meeting. Data for this

inhibitor of the Nedd8-activating enzyme showed the molecule

significantly inhibited tumor growth in xenograft models for colorectal

cancer and several types of lymphoma. MLN4924 is expected to enter

Phase I trials in early 2008.

Conference Call and Presentation Reminder

Dr. Dunsire and members of the Millennium leadership team will present additional details on these results this m
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Mass. , Aug. 3, 2015  Merck KGaA, ... for innovative and top-quality high-tech products in the healthcare, ... with the US-based company Nano-C, their development and launch ... of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... in the growing OPV sector. Novel derivatives: ...
(Date:8/3/2015)... 2015   Intrexon Corporation (NYSE: XON ... second quarter 2015 financial results after the market closes ... will host a conference call at 5:30 PM ET ... update. The conference call may be accessed ... asking to join the "Intrexon Corporation Call."  Participants may ...
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of the ... in Marshall. The Ralco Enrichment Center is an interactive experience where the public can ... lives. This unique exhibit also features a birthing center for fair goers to watch ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... Feb. 24, 2011 ViroPharma Incorporated (Nasdaq: VPHM ... and year ended December 31, 2010. In 2010, ... net product sales, including $177 million in net sales of ... income of $157 million, representing 88 percent growth over the ...
... DIEGO, Feb. 23, 2011 Ardea Biosciences, Inc. (Nasdaq: ... of its previously announced public offering of common stock ... additional 412,500 shares of common stock to cover overallotments. ... shares offered at a price to the public of $26.00 per ...
... 2011 Quanterix Corporation, a single molecule diagnostics company ... and in vitro diagnostics markets, today announced the online ... Si ngle Mo lecule A rray ... one straightforward measurement.  The article appears in the journal ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results 11Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering 2Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering 3Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability 2
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... 2010 Country roadways can be hazardous for moose and ... elk and caribou in North America and Europe each year. ... pools that collect following pavement deicing. Because moose ... weighing up to 720 kilograms, their salt cravings can pose ...
... the Free State in South Africa (Ren Fourie and Charles ... (Rudy Jocqu) discovered very poorly known purse-web spiders of the ... new to science. The study was published in the open ... unique about purse-web spiders is that, in contrast to trapdoor ...
... have shown that a new experimental vaccine helps to ... from CSIRO,s Australian Animal Health Laboratory (AAHL) will announce ... Australian Veterinary Association conference in Adelaide today. "Our ... the infection of horses with Hendra virus," Dr Middleton ...
Cached Biology News:Of moose and men 2Vaccine protects from deadly Hendra virus 2
... The ApopTag Fluorescein Direct ... detects apoptotic cells in situ ... The DNA fragments are tagged ... nucleotide. The kit provides fluorescence ...
... CHEMICON APO-BRDU Kit is a ... breaks and total cellular DNA to detect ... kit contains the instructions and reagents required ... and negative control cells for assessing reagent ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... The Biomek FXP is the latest entry in ... greater positional accuracy and increased robustness, it can ... It can be configured with either one or ... the Biomek FXP sets the standard for flexible ...
Biology Products: